CANCER stem cells, which fuel the growth of fatal tumours, can be knocked out by a one-two combination of antibiotics and Vitamin C in a new experimental strategy, published by researchers at the University of Salford, UK.
The antibiotic, Doxycycline, followed by doses of ascorbic acid (Vitamin C), were surprisingly effective in killing the cancer stem cells under laboratory conditions, according to the research published in the journal Oncotarget.
In boxing terms, this would be the equivalent of two blows delivered in rapid succession; a left-hand jab, followed by a right cross.
The researchers say their method offers a new explanation for how to prevent cancer cells from becoming treatment-resistant and how combinations therapies can be developed to overcome drug resistance.
Starve cancer cells
Professor Michael Lisanti, who designed the study, explained: “We now know that a proportion of cancer cells escape chemotherapy and develop drug resistance; we established this new strategy to find out how they do it.
“We suspected the answer lay in the fact that certain cancer cells – which we call metabolically flexible – are able to switch their fuel source. Thus, when the drug treatment reduces the availability of a particular nutrient, the flexible cancer cells can feed themselves with an alternative energy source.”
This new combination approach prevents cancer cells from changing their diet (metabolically inflexible), and effectively starves them, by preventing them from using any other available types of bio-fuels.
The team at the University of Salford’s Biomedical Research Centre, added Doxycycline in ever increasing doses over a three-month period, to induce metabolic inflexibility. The result was to leave the cancer cells alive, but severely attenuated and depleted, so that they would be much more susceptible to starvation, by a second metabolic “punch”.
First, the researchers inhibited the tumour cell mitochondria, by restricting the cancer cells only to glucose as a fuel source; then, they took away their glucose, effectively starving the cancer cells to death.
“In this scenario, Vitamin C behaves as an inhibitor of glycolysis, which fuels energy production in mitochondria, the “powerhouse” of the cell, explained co-author Dr Federica Sotgia.
The Salford team recently showed Vitamin C to be up to ten times more effective at stopping cancer cell growth than pharmaceuticals such as 2-DG, but they say that when Vitamin C is combined with an antibiotic, it is up to ten times more effective, making it nearly 100 times more effective than 2-DG.
As Doxycycline and Vitamin C are both relatively non-toxic, this could dramatically reduce the possible side-effects of anti-cancer therapy.
The Salford team also identified eight other drugs that could be used as a “second-punch” after the antibiotic regime, including berberine (a natural product) – and a number of cheap non-toxic FDA approved drugs.
Professor Lisanti added: “This is further evidence that Vitamin C and other non-toxic compounds may have a role to play in the fight against cancer.
“Our results indicate it is a promising agent for clinical trials, and a as an add-on to more conventional therapies, to prevent tumour recurrence, further disease progression and metastasis.”
The Latest on: Cancer stem cells
Global Stem Cell Banking Market Industry 2025 by Worldwide Market Size, Key Vendors, Growth Rate, Drivers, Volume & Forecast Report
on April 18, 2018 at 12:31 pm
On the basis of origin, the stem cell banking market is segmented into embryonic, adult, and germinal. By Application the market is segmented into cerebral palsy, thalassemia, leukemia, diabetes, cancer, cardiac diseases, autism, others. On the basis of ... […]
Asterias Biotherapeutic: Spinal Injury Stem Cell Therapy Play
on April 18, 2018 at 5:59 am
and use their IP protected technologies to turn these stem cells into specific cell therapies, AST-OPC1 for SCI, and two others for cancer immunology, which preclinical studies show to be most beneficial for the indications. The scientific rational of AST ... […]
Breakthrough microscope revolutionizes live cell imaging of stem cells
on April 18, 2018 at 4:55 am
Observing living stem cells under different conditions allows medical advancements in fighting cancer, degenerative diseases such as Alzheimer or organ failures such as heart diseases. The goal is not only to acquire snapshots of dynamic biological systems ... […]
Three-time cancer survivor finishes Boston Marathon 13 hours after start
on April 17, 2018 at 11:47 am
The determined wife and mother of two endured intense chemotherapy, two relapses and a stem cell transplant, before turning to Boston's Dana-Farber Cancer Institute. "They said, this time we're going to nuke you and throw all these crazy things that we ... […]
County Commissioner John Morroni begins another fight against cancer
on April 17, 2018 at 10:56 am
Four years later, during a follow-up CAT scan done the second week in December, he found out the cancer had returned. Morroni underwent a stem cell transplant and “toxic” chemotherapy. That treatment was more difficult and took longer. It also required ... […]
Her identical twin saved her life 25 years ago. Now they're cancer activists
on April 17, 2018 at 7:08 am
Stadtmauer, who treated Marilyn at Penn and is now chief of the blood cancer section. Penn was among centers testing whether bone-marrow transplantation (now called stem-cell transplantation) could improve survival, as it had in leukemia and lymphoma. […]
Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
on April 17, 2018 at 6:28 am
The poster presentation (abstract: CT130), titled “Clinical trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T cells in relapsed/refractory (r/r) multiple myeloma (MM),” is being presented at the American Association for Cancer Research (AACR ... […]
BlueRock Therapeutics Establishes R&D Site in New York City and Formalizes Collaboration with Memorial Sloan Kettering Cancer Center
on April 17, 2018 at 5:08 am
as well as the formalization of a significant sponsored research collaboration with the Center for Stem Cell Biology at Memorial Sloan Kettering (MSK) Cancer Center. The collaboration will focus on translating MSK expertise in creating multiple types of ... […]
A potential setback in the personalized medicine of cancer
on April 16, 2018 at 9:05 pm
Ras, the Holy Grail of targets to fight cancer In addition to being the first ... into proliferating responses within the cell. When RAS proteins are eliminated in mouse stem cells, these remain in a sort-of suspended state: they do not grow, they do ... […]
Cancer Stem Cells Market Worth $1.6 Billion by 2025 | CAGR: 9.98%: Grand View Research, Inc.
on April 9, 2018 at 2:19 am
The global cancer stem cells market size is expected to reach USD 1.6 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.98% during the forecast period. Although stem cell-based cancer treatment is facing ... […]
via Google News and Bing News